Background: Esophageal cancer (EC) is the seventh most common cancer and the sixth most common cause of cancer-related deaths worldwide. It is associated with a poor prognosis having an 18% 5-year overall survival rate. This study examined treatment patterns and healthcare resource utilization (HRU) in patients who initiated first-line (1L) systemic therapy for advanced esophageal squamous cell carcinoma (ESCC) across geographies. Methods: A retrospective, non-interventional study was conducted among 639 physicians from Asian (Japan, Korea, Taiwan and China) and Western (US, Canada, France, Germany, Italy, Spain, UK) countries (September-October 2018). Patient characteristics and treatment-related data were collected from the 3-4 most recent patient medical charts for 1L systemic treatment or best supportive care (BSC). Results: 1,049 ESCC patients were included (Asia=40.2%; West=59.8%), with a mean age of 62.9±10.6 years and 82.7% male. 81.8% (n=858) received 1L systemic treatment (Asia=71.1%; West=89.0%). The five most common 1L treatment regimens were cisplatin + 5-FU (27.4%), carboplatin + paclitaxel (8.4%), FOLFOX (8.0%), 5-FU (+leucovorin) (6.6%), and carboplatin + 5-FU (5.9%), although differences were observed by geography. Rates of adverse event [AE]-related emergency room visits and hospitalizations for patients on systemic treatment were 14.5% and 12.9%, respectively, with increased rates for Asian compared to Western patients (P=0.006). The percentage of 1L patients with an ECOG performance status (PS) 2-4 following treatment was 36.1% (Asia=35.3%; West=36.4%; P=0.690). Response to 1L treatment and outcomes following 1L treatment (at the time of data collection) were similar by geography, with 36.2% progressing to a next line of therapy and 13.2% who died. Conclusions: Treatment options for 1L therapy in ESCC vary by region. Variation by Asian and Western countries were observed for AE-related HRU but not for PS following treatment, treatment response, or outcomes. Burden of disease for these 1L patients exists regardless of geography suggesting a need for improved treatments.
HSR21-055: Treatment Patterns and Healthcare Resource Utilization in First-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma in Asian and Western Countries
Authors:
,
, and
Dena Jaffe
PhD
Dena Jaffe
Kantar Health, Tel Aviv, Israel
Search for other papers by Dena Jaffe in
Current site
Google Scholar
PubMed
Search for other papers by Dena Jaffe in
Current site
Google Scholar
PubMed
Marc DeCongelio
MS
Marc DeCongelio
Kantar Health, New York, NY
Search for other papers by Marc DeCongelio in
Current site
Google Scholar
PubMed
Search for other papers by Marc DeCongelio in
Current site
Google Scholar
PubMed
Joseph Gricar
PhD
Joseph Gricar
Bristol-Myers Squibb, Princeton, NJ
Search for other papers by Joseph Gricar in
Current site
Google Scholar
PubMed
Search for other papers by Joseph Gricar in
Current site
Google Scholar
PubMed
© 2019-2023 National Comprehensive Cancer Network